Funded Projects

We understand a lot about how the brain gets rewired when learning a new skill by repetitive practice, such as hitting a curveball. However, how learning and experience alter the innate behaviors that we are born with is poorly understood.

Sleep is a critical behavioral state that fulfills essential needs for health, including clearing waste products (e.g., protein aggregates) from the brain. But sleep is not everlasting. As humans age, sleep quality strikingly deteriorates, and this decline is associated with dementias (e.g., Alzheimer’s disease).

Millions of people are blind, yet we still don’t have the technology to satisfactorily restore vision. I aim to create a prosthetic device to do so. This device can be implanted in the eyes of a blind patient, resting on a tissue layer called the retina.

Brain-computer interfaces (BCIs) are systems that enable using neural activity to control and interact with external devices. For people who lose the ability to move or speak due to injury or disease, BCIs provide a potential avenue to restore this loss of function.

It is more common nowadays for people to have their own wearable devices to measure physiological signals like heart rate and respiration to keep track of physical diseases. However, monitoring decline in cognitive functions or development of neurodegenerative diseases, such as Parkinson’s (PD), is still complex and tricky.

While acute pain is an important biological signal in response to injured tissue, chronic pain occurs when the pain signaling outlasts the initial injury and has deleterious effects on health and quality of life. Chronic pain represents an enormous public health burden with few therapeutic options.

With an aging population, neurodegenerative disorders contribute increasingly to our global health burden with no cure or effective treatments. Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are two neurodegenerative disorders that are distinct in clinical presentation (ALS impairs movement/breathing, whereas FTD impairs behavior/cognition).

There is one characteristic of all neurodegenerative diseases: the accumulation and aggregation of abnormal proteins in the patient’s brain. These aggregations are thought to induce neuronal cell death and brain degeneration.

With an aging population, neurodegenerative disorders contribute increasingly to our global health burden with no cure or effective treatments. Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are two neurodegenerative disorders that are distinct in clinical presentation (ALS impairs movement/breathing, whereas FTD impairs behavior/cognition).

The causes of neurodegenerative disorders like multiple sclerosis or Alzheimer’s disease are incompletely understood, hindering our ability to gain precise diagnoses and design effective therapeutics. Understanding how the circadian rhythms regulate myelin-forming precursors will impart unique insights into normal and aberrant myelination and will have a positive impact on developing therapeutic strategies to restructure myelin.

This team will use their Neuroscience:Translate award to develop a large-scale bi-directional neural interface that will restore high-fidelity vision to people blinded by retinal degeneration.

This team will use their Neuroscience:Translate award to employ a novel therapeutic technique to correct pathogenic mutations causing Parkinson’s disease.

This team aims to revolutionize future stroke treatment both in clinics and at home by combining a brain-computer interface and augmented reality (AR) into a single rehabilitation platform.

This team aims to advance augmentative and alternative communication technology for people with communication disorders and enable new forms of human-computer interaction by combining novel materials science with modern machine learning.

This team will use their Neuroscience:Translate award to develop an entirely new class of ischemic stroke treatment device that will lead to improved clot extraction to improve the success of endovascular thrombectomy.

This team will use their Neuroscience:Translate award to develop the first wearable ultrasound (US) device for the treatment of inflammatory diseases, such as Rheumatoid Arthritis (RA) and Inflammatory Bowel Disease.

We propose a new line of research whose goal is to examine the druggability of a protein-protein interface involving ApoE, an apolipoprotein whose gene variants represent the strongest genetic risk factor for AD.

People with Parkinson’s Disease (PD) have different types of bacteria in their guts compared to people without neurological diseases. We will study which gut bacteria for people with PD to gain a better understanding of how gut bacteria contribute to inflammation in the body and in the brain or people with this condition. 

We propose to apply mass spectrometry techniques to measure BHB-Phe and other KD metabolites in children undergoing KD for refractory epilepsy at Stanford. Further, in a mouse model of refractory genetic epilepsy, we will compare targeted BHB-Phe treatment to full KD treatment using transcriptomics, EEG assessment of seizures and cognitive testing.

Why do all our brains mature and age in different ways, leading to different cognitive and behavioral outcomes? We envision a novel method that “copies” the information from the RNAs made by the neurons to sensor RNAs we artificially introduce into live animals. 

In this study, we aim to (i) perform a feasibility study to determine the acceptance and feasibility of performing such recordings in the AN and ARFID eating disorders population and (ii) test the hypothesis that the electrophysiologic monitoring of the brain and stomach is associated with a clinically validated behavioral measure of interoception involving water distention of the stomach.